APA (7th ed.) Citation

R, D., JC, S., K, C., MA, G., A, V., & BK, W. (2024). KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells. Diabetes, 73(4), 585. https://doi.org/10.2337/db23-0506

Chicago Style (17th ed.) Citation

R, Devkota, Small JC, Carbone K, Glass MA, Vetere A, and Wagner BK. "KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells." Diabetes 73, no. 4 (2024): 585. https://doi.org/10.2337/db23-0506.

MLA (9th ed.) Citation

R, Devkota, et al. "KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells." Diabetes, vol. 73, no. 4, 2024, p. 585, https://doi.org/10.2337/db23-0506.